Jennifer Baldock Sells 10,082 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) insider Jennifer Baldock sold 10,082 shares of the stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $13.70, for a total transaction of $138,123.40. Following the completion of the sale, the insider owned 332,272 shares of the company’s stock, valued at approximately $4,552,126.40. The trade was a 2.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Surgery Partners Trading Down 2.6%

Shares of Surgery Partners stock opened at $12.95 on Wednesday. The stock has a market cap of $1.68 billion, a P/E ratio of -20.89 and a beta of 1.95. The stock’s 50 day simple moving average is $15.10 and its 200-day simple moving average is $17.93. Surgery Partners, Inc. has a 1-year low of $12.25 and a 1-year high of $24.60. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.87 and a quick ratio of 1.71.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings results on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.19). Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The company had revenue of $885.00 million during the quarter, compared to analyst estimates of $866.54 million. During the same period in the prior year, the business posted $0.44 EPS. Surgery Partners’s revenue for the quarter was up 2.4% compared to the same quarter last year. Analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Surgery Partners announced that its Board of Directors has initiated a stock buyback plan on Thursday, February 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 9.7% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its shares are undervalued.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus remains constructive — several brokerages rate SGRY as a “Moderate Buy,” which supports baseline investor demand. Brokerage Recommendation
• Positive Sentiment: Investor conference access: Management presented at the Barclays 28th Annual Global Healthcare Conference (Mar 10), providing a forum to reiterate guidance and margin improvement plans — useful upside catalyst if commentary is clear and credible. Prepared Remarks Transcript
• Positive Sentiment: Short interest fell ~15.7% in February (still ~11% of float but lower than mid‑month), which reduces one source of bearish positioning and could limit further short-driven price pressure.
• Neutral Sentiment: Prepared remarks and Q4 write‑ups: Recent transcripts and industry Q4 summaries provide more detail on volumes and outpatient trends but contain no single new, market‑moving disclosure. Q4 Coverage
• Negative Sentiment: Activist pressure: Ortelius Capital is pushing for board changes and asset sales, increasing the chance of near‑term strategic disruption, management turnover or contentious proxy fights. Activist Story
• Negative Sentiment: Fraud probe announced: Law firm Levi & Korsinsky opened an investigation into prior management statements on margin expansion, raising potential legal/settlement risk and heightening investor uncertainty. Fraud Investigation
• Negative Sentiment: Significant insider selling: Multiple executives (CEO, CFO and other officers) sold sizable blocks the week of Mar 5–6 at roughly $13.60–$13.93, which the market often interprets negatively for near‑term confidence. Representative SEC filing: CEO Sale Filing
• Negative Sentiment: Recent earnings execution: The March 2 Q4 report showed a meaningful EPS miss (revenue slight beat but EPS well below street), highlighting execution/margin risk that underpins some of the legal and activist scrutiny.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp boosted its stake in Surgery Partners by 313.1% during the third quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company’s stock worth $27,000 after buying an additional 930 shares during the period. Caitong International Asset Management Co. Ltd increased its position in shares of Surgery Partners by 45,640.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,287 shares of the company’s stock valued at $49,000 after acquiring an additional 2,282 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Surgery Partners by 128.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,702 shares of the company’s stock valued at $58,000 after acquiring an additional 1,519 shares during the period. Aquatic Capital Management LLC purchased a new stake in shares of Surgery Partners in the 3rd quarter valued at approximately $121,000. Finally, State of Alaska Department of Revenue acquired a new position in shares of Surgery Partners in the 3rd quarter worth approximately $151,000.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on SGRY shares. Barclays lowered their price target on shares of Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 3rd. UBS Group cut their price objective on shares of Surgery Partners from $29.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. JPMorgan Chase & Co. decreased their target price on shares of Surgery Partners from $27.00 to $20.00 and set a “neutral” rating on the stock in a report on Monday, November 24th. Royal Bank Of Canada dropped their price target on shares of Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a research note on Wednesday, March 4th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Surgery Partners in a report on Wednesday, March 4th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.60.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.